Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
CAMBRIDGE, Mass., Nov. 06, 2017 -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. In addition, Spero Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the initial public offering price. The shares began trading on The Nasdaq Global Select Market on November 2, 2017 under the ticker symbol “SPRO.”
BofA Merrill Lynch, Cowen and Stifel acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering was made by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806; and from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Spero
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
Spero Media and Investor Contact
Sharon Klahre
Director, Investor Relations
857-242-1547
[email protected]
